reports
- Guy Sips
- Hilde Van Boxstael
- Michiel Declercq
- Wim Hoste
- Wim Lewi
EXMAR NV: 1 director
A director at EXMAR NV bought 289,026 shares at 11.500EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
- Bruno Cavalier
- Stephane Houri
IPS IPSOS
LHA DEUTSCHE LUFTHANSA AKTIENGESELLSCHAFT
GET GETLINK SE
FRA FRAPORT AG
ELIOR ELIOR GROUP SA
DG VINCI SA
ALESK ESKER SA
BEKB BEKAERT SA
DB1 DEUTSCHE BOERSE AG
MC LVMH MOET HENNESSY LOUIS VUITTON SE
LI KLEPIERRE SA
COV COVIVIO SA
FGR EIFFAGE SA
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
SBMO SBM OFFSHORE NV
MF WENDEL SE
EN BOUYGUES SA
STF STEF
INF INFOTEL SA
SCR SCOR SE
DEC JCDECAUX SA
ASY ASSYSTEM SA
EL ESSILORLUXOTTICA SA
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
PSM PROSIEBENSAT.1 MEDIA SE
COLR ETABLISSEMENTEN FRANZ COLRUYT N.V.
BRBY BURBERRY GROUP PLC
FII LISI SA
GOE GROUPE GORGE SA
KER KERING SA
ALTA ALTAREA SCA
VNA VONOVIA SE
ZAL ZALANDO SE
ERA ERAMET SA
ICAD ICADE SA
01913 PRADA S.P.A.
IMPN IMPLENIA AG
REP REPSOL SA
COR CORTICEIRA AMORIM SGPS SA
RAA RATIONAL AG
DOKA DORMAKABA HOLDING AG
DLG DE'LONGHI S.P.A.
ELI ELIA GROUP SA/NV
MONC MONCLER SPA
ONTEX ONTEX GROUP N.V.
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COL INMOBILIARIA COLONIAL SOCIMI SA
CSM CORBION NV
COFA COFACE SA
HBH HORNBACH HOLDING AG & CO. KGAA
XFAB X-FAB SILICON FOUNDRIES SE
ARGX ARGEN-X SE
JEN JENOPTIK AG
VRLA VERALLIA SAS
ALG ALLEGRO.EU SA
INPST INPOST S.A.
FPE3 FUCHS PETROLUB SE
ALAFY AFYREN
AM DASSAULT AVIATION
CTPNV CTP NV
EAPI EUROAPI
DEME DEME GROUP NV
FLE PEGASUS ENTREPRENEURIAL ACQUISITION CO EURO BV
SHUR SHURGARD SELF STORAGE LIMITED
AF AIR FRANCE - KLM
VIRI VIRIDIEN
CAN CANAL+
- Damien Choplain
- Martial Descoutures
- Bruno Cavalier
- Jean Danjou
- Guy Sips
- Hilde Van Boxstael
- Sharad Kumar S.P
- Thomas Vranken
- Wim Lewi
- Damien Choplain
- Martial Descoutures
- Thomas Vranken
argenx Strategic priorities for 2025
argenx discloses its strategic priorities for 2025, focusing on the expected PFS approval, as well as various label-expansion, registrational and PoC studies across Vyvgart (efgartigimod), empasiprubart, ARGX-109 and others. With preliminary net sales of $ 2.2bn, topline comes in slightly ahead of our and CSS estimates. We roll over our DCF model and adjust our TP to € 670, Accumulate reiterated.
argenx Highlights 2025 Strategic Priorities
argenx Highlights 2025 Strategic Priorities Reported $2.2 billion in preliminary* full-year 2024 global product net sales, inclusive of $737 million in fourth quarter sales Pre-filled syringe FDA PDUFA on track for April 2025 to support reaching patients earlier in treatment paradigm 10 ongoing registrational studies in 2025 across efgartigimod and empasiprubart enable next wave of indications Empasiprubart to be evaluated in two head-to-head registrational studies against IVIg to position C2 inhibitor for broad, early-line use in MMN and CIDP Transition to sustainable profitability...
Argen X SE: 1 director
A director at Argen X SE sold after exercising options/sold 9,950 shares at 608.600EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
- Hilde Van Boxstael
- Wim Hoste
- Wim Lewi
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference January 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the arge...
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Thomas Vranken
argenx FIRST LOOK: CIDP approvals now include Japan
argenx announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the application for Vyvdura (SC efgartigimod) in adults with CIDP. Following gMG and ITP, CIDP represents the third indication for Vyvgart/Vyvdura in the country, and obtained self-administration in this geography as well. We reiterate our € 615 TP and Accumulate rating.
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronid...
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across three indications December 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from sever...
- Hilde Van Boxstael
- Wim Hoste
- Wim Lewi
- Guy Sips
- Kristof Samoy
- Michiel Declercq
- Wim Hoste
Local Champions Midcap Conference Book 12.12.2024
This conference book is your guide to our annual Local Champions Mid Cap Conference set to take place on Thursday, 12 December 2024 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or attend small group sessions with the top management and/or IR of the following companies: BARCO | BEKAERT | DECEUNINCK | EKOPAK | EVS | GREENYARD | IBA | JENSEN | ONTEX | RECTICEL | VAN DE VELDE | WHAT'S COOKING? | XFAB
argenx to Present at Upcoming Investor Conferences
argenx to Present at Upcoming Investor Conferences November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December. Citi’s 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL. 7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wednesday, December 4 at 1:45 p.m. ET in Coral Ga...
AB InBev Becomes Official Beer Partner of FIFA Club World Cup 2025™
NEW YORK--(BUSINESS WIRE)-- AB InBev (Euronext: ABI) (MEXBOL: ANB) (JSE: ANH) (NYSE: BUD), the world’s leading brewer, has extended its nearly 40-year partnership with FIFA to include the FIFA Club World Cup 2025™ taking place in the United States from June 15th to July 13th. AB InBev is also a sponsor of FIFA World Cup 2026™, which will be jointly hosted by 16 cities across Canada, Mexico and the United States. This press release features multimedia. View the full release here: AB InBev: Official Beer Partner of FIFA Club World Cup (Graphic: Business Wire) The expanded partnership reinforces...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.